The Latest Cardiac and Vascular News
ST. LOUIS PARK, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company, is leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation with more than a decade of commercial experience in treating over 1,800 patients globally with the transapical […]
ST. LOUIS PARK, Minn., March 14, 2022 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced the appointment of Martin B. Leon, M.D. as Executive Chair of the U.S. early feasibility study […]
ST. LOUIS PARK, Minn., Nov. 22, 2021 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced positive 30-day results following the first successful worldwide procedure using multiple chords to a single anchor. The […]
ST. LOUIS PARK, Minn., Oct. 04, 2021 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced successful completion of the first-in-human procedure with the NeoChord NeXuS Transcatheter Mitral Chordal Repair technology (TMVr). […]
ST. LOUIS PARK, Minn., April 23, 2019 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced today that it has secured additional funding as an extension of its Series D equity financing, which […]
ST. LOUIS PARK, Minn., Nov. 05, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced today that it has completed a $25 million Series D equity financing. Proceeds from the financing […]
ST. LOUIS PARK, Minn., Sept. 04, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced that it has successfully treated the first patients in Asia using the NeoChord procedure at Queen […]
ST. LOUIS PARK, Minn., Jan. 22, 2018 (GLOBE NEWSWIRE) — NeoChord, a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced a research collaboration with the Skirball Center for Innovation (SCI) at the Cardiovascular Research Foundation (CRF)to accelerate development of the company’s transcatheter […]
ST. LOUIS PARK, Minn., July 10, 2017 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of Andrew ElBardissi, M.D. to its Board of Directors, effective immediately. Dr. ElBardissi is replacing Avi Kometz, […]
